Inhibition of human immunodeficiency virus expression by sense transcripts encoding the retroviral leader RNA.
Towards gene therapy for the treatment of human immunodeficiency virus type 1 (HIV-1) infections, we tested the potency of several antiviral constructs in transient HIV-1 production assays. Whereas little effect was obtained with antisense- and TAR decoy-constructs, we measured efficient inhibition of HIV-1 mRNA translation and virion production in the presence of HIV-1 leader-containing transcripts. The infectivity of these virions was also reduced by this sense inhibitor RNA. These results suggest that leader-encoded functions, like the dimer-linkage structure, can be used to specifically inhibit HIV expression in trans.
Berkhout
B
B
Department of Virology, Academic Medical Center, University of Amsterdam, The Netherlands.
van Wamel
J L
JL
D000998:Antiviral Agents / Q000494:pharmacology*; D015152:Blotting, Northern; D015967:Gene Expression Regulation, Viral; D016325:HIV Long Terminal Repeat / Q000235:genetics*; D015497:HIV-1 / Q000187:drug effects* / Q000502:physiology; D006367:HeLa Cells; D006801:Humans; D016372:RNA, Antisense / Q000494:pharmacology; D012367:RNA, Viral / Q000494:pharmacology*; D016601:RNA-Binding Proteins / Q000235:genetics; D012191:Retroviridae Proteins / Q000235:genetics; D014158:Transcription, Genetic; D014779:Virus Replication / Q000187:drug effects; D000099253:Trans-Activation Responsive RNA-Binding Protein
D000998:Antiviral Agents; D016372:RNA, Antisense; D012367:RNA, Viral; D016601:RNA-Binding Proteins; D012191:Retroviridae Proteins; D000099253:Trans-Activation Responsive RNA-Binding Protein